Researchers from UC San Diego’s Scripps Institution of Oceanography and UCLA announced the creation of an engineered ...

Mitochondrial diseases affect approximately 1 in 5,000 people worldwide, causing debilitating symptoms ranging from muscle weakness to stroke-like episodes.

Mesoblast Limited’s FDA-approved Ryoncil and advancing Revascor target major conditions like SR-aGVHD and heart failure. See ...

Many mitochondrial diseases have been difficult to study and treat due to the inherent challenges in accessing mitochondrial DNA (mtDNA). Now, researchers have optimized mitochondrial-targeted ...

Zevaskyn won FDA approval upon Abeona’s second filing of a biologics license application (BLA) for the therapy.

Researchers at the University of Minnesota have completed a first-in-human clinical trial testing a CRISPR/Cas9 gene-editing technique to help the immune system fight advanced gastrointestinal (GI) ...

HAYA Therapeutics, SA, a biotechnology company pioneering precision RNA-guided regulatory genome targeting therapeutics that reprogram disease-driving cell states for rare, common, chronic and ...

APLA Health proudly celebrates the grand reopening of its Long Beach Health Center, unveiling a significant expansion that ...

RoosterBio Inc. has partnered with Thermo Fisher Scientific to accelerate the availability of new, potentially life-saving ...

Current treatment options for HI brain injury are limited, but mesenchymal stem cell (MSC) therapy is a promising strategy to boost neuroregeneration after injury. Optimization strategies to further ...